Katrina Selsor
Primary Care · Sparta, MONPI 1073020673
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 470 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 15.3% — the pattern of someone who eats at a lot of different presentations. Among primary care clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 470 payments — averaging $13.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$953
- Lilly USA, LLC$729
- AbbVie$681
- Novo Nordisk$565
- Otsuka America Pharmaceutical, Inc.$435
- Teva Pharmaceuticals USA, Inc.$402
- plus $2K from 30 others
What the payments were for
- Food & beverage$6,222100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 45 | $953 |
| Lilly USA, LLC | 51 | $729 |
| AbbVie(2 entities) | 60 | $681 |
| Novo Nordisk | 113 | $565 |
| Otsuka America Pharmaceutical, Inc. | 26 | $435 |
| Teva Pharmaceuticals USA, Inc. | 27 | $402 |
| Merck | 15 | $255 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 14 | $242 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $217 |
| Corium, LLC | 16 | $206 |
| Boehringer Ingelheim | 10 | $147 |
| GSK | 10 | $144 |
| Johnson & Johnson | 9 | $130 |
| Abbott | 7 | $128 |
| Neurocrine Biosciences, Inc. | 6 | $125 |
| Lundbeck LLC | 6 | $111 |
| Axsome Therapeutics, Inc. | 4 | $100 |
| Novartis | 6 | $86 |
| Globus Medical | 2 | $71 |
| Daiichi Sankyo Inc. | 4 | $66 |
| Pfizer | 4 | $61 |
| Collegium Pharmaceutical, Inc. | 3 | $54 |
| Sumitomo Pharma America, Inc. | 3 | $50 |
| Astellas Pharma US Inc | 2 | $35 |
| Exact Sciences | 2 | $32 |
| Avion Pharmaceuticals | 2 | $31 |
| Mylan Specialty L.p. | 2 | $28 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| Radius Health, Inc. | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| Amgen | 1 | $14 |
| Organon | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,222 in reported general payments places this provider in the 95th percentile of 106 primary care providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 38 | $59,934 |
| MounjaroTirzepatide | 40 | $42,042 |
| EliquisApixaban | 49 | $31,869 |
| OzempicSemaglutide | 14 | $20,835 |
| Pyridostigmine Bromide ErPyridostigmine Bromide | 13 | $13,555 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $12,771 |
| FarxigaDapagliflozin Propanediol | 18 | $12,162 |
| Spiriva RespimatTiotropium Bromide | 23 | $11,636 |
| LinzessLinaclotide | 18 | $11,543 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $11,478 |
| TrintellixVortioxetine Hydrobromide | 13 | $10,168 |
| MyrbetriqMirabegron | 16 | $7,301 |
| MovantikNaloxegol Oxalate | 12 | $5,021 |
| VascepaIcosapent Ethyl | 12 | $4,183 |
| Varenicline Tartrate | 15 | $3,064 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $435 | $59,93438 claims |
| Lilly USA, LLCMounjaro | $729 | $42,04240 claims |
| PfizerEliquis | $61 | $31,86949 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $953 | $23,63936 claims |
| Novo NordiskOzempic | $565 | $20,83514 claims |
| GSKTrelegy Ellipta | $144 | $12,77118 claims |
| Boehringer IngelheimSpiriva Respimat | $147 | $11,63623 claims |
| AbbVieLinzess | $681 | $11,54318 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $217 | $10,16813 claims |
| Astellas Pharma US IncMyrbetriq | $35 | $7,30116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 106 primary care providers in Missouri.
Other primary care in Sparta
- Taylor HeathSparta$3K
- Danielle ToalCape Girardeau$15K
- Joy MurphySaint Louis$7K
- Kelly EspositoSaint Louis$6K
- Elizabeth YoungSaint Louis$5K
- Carol HarringtonIndependence$4K
- Melanie HenryHayti$4K
- Heather BealSaint Louis$4K
- Ashley TitchenalSaint Louis$3K
- Avonne RosarioKansas City$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.